The Health Benefits Of Coffee
More evidence coffee may slow liver disease
Last Updated: 2010-11-03 17:30:03 -0400 (Reuters Health)
"There's definitely a relationship, we don't know exactly what it is yet," between coffee and fibrosis, Dr. Harrison said. He called the findings "provocative" and "hypothesis-generating," noting that a prospective interventional study would be needed to determine a causal relationship. "
By Anne Harding
NEW YORK (Reuters Health) - Drinking coffee could help slow the progression of fibrosis in patients with fatty liver disease, according to new research presented at the American Association for the Study of Liver Diseases' annual meeting in Boston.
And a separate study presented at the same meeting found that patients with chronic hepatitis C who drank the most coffee and had failed standard treatment fared much better with retreatment.
Since the early 1990s, several studies have suggested benefits of coffee drinking for liver health, Dr. Jeffrey W. Molloy and Dr. Stephen A. Harrison and their colleagues at Brooke Army Medical Center in San Antonio, Texas, note in their report. In 2009, Dr. Harrison noted in an interview, two studies showed drinking about 2.5 cups of coffee daily reduced the risk of hepatic steatosis in patients with hepatitis C.
For the current study, the Texas researchers used a group of asymptomatic individuals whom they had initially screened for liver disease with ultrasound, giving them a "nice clean cohort of patients" with no liver disease who served as controls, Dr. Harrison told Reuters Health. Patients with ultrasound tests suggesting fatty liver disease underwent percutaneous liver biopsies.
Their analysis included 177 controls, 89 patients with simple steatosis, 31 patients with nonalcoholic steatohepatitis (NASH) and stage 0-1 fibrosis, and nine patients with NASH and stage 2-4 fibrosis.
Among the NASH patients, the researchers found, those with less severe disease drank significantly more coffee than those with more severe fibrosis. The patients with NASH stage 0-1 fibrosis consumed an average of 413 mg of caffeine and 312 mg of coffee, compared to 189 mg of caffeine (p=0.035) and 79 mg of coffee (p=0.03) for the NASH stage 2-4 fibrosis patients.
The 75th quartile for daily coffee consumption was 343 mg, or about 2.5 cups, the researchers found. Ten percent of patients who consumed this much coffee had NASH stage 2-4 disease, compared to roughly half of the patients who didn't drink coffee at all. Logistic regression analysis showed that the risk of severe fibrosis declined as caffeine and coffee consumption rose (p=0.023 for both).
"There's definitely a relationship, we don't know exactly what it is yet," between coffee and fibrosis, Dr. Harrison said. He called the findings "provocative" and "hypothesis-generating," noting that a prospective interventional study would be needed to determine a causal relationship.
Nevertheless, he and his colleagues conclude, "moderate caffeine and/or coffee consumption may be a benign adjunct to the comprehensive management of NASH patients."
In the second study, Dr. Neal D. Freeman of the National Cancer Institute and his colleagues found that among 885 patients with chronic hepatitis C who failed standard treatment with interferon, those who drank more coffee responded better to retreatment with peg interferon alfa 2a and ribavirin.
The median log10 drop from baseline to week 12 of retreatment was 1.7 among non-coffee drinkers, compared to 3.7 for those who drank three cups or more daily (p for trend across categories less then 0.0001).
There also were "highly statistically significant trends" in early virologic response (EVR, defined as a two log10 drop in HCV RNA at week 12), undetectable HCV RNA at week 20 of treatment, and sustained virologic response (SVR, at week 72, 24 weeks after the end of treatment).
For example, 11.3% of non-coffee drinking patients had an SVR, compared to 25.8% of patients who drank at least three cups a day. The EVR rate was 45.7% in non-coffee drinkers and 72.7% in the heaviest coffee drinkers. And among the non-coffee drinkers, 26.3% had undetectable levels of HCV RNA at week 20 of the study, compared to 52.3% of people who drank three or more cups daily (p for trend in all three categories less then 0.0001).
Get Updates For HCV New Drugs Delivered By Email
Check Out The Website
Hepatitis C New Drug Research And Liver Health
RSS Feed; Website Updates
HCV In The News
DDW 2013 - May 18-21, 2013 - Orlando, FL
Digestive Disease Week - The conference will showcase the latest advances in GI research, medicine and technology in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery
Hot Topics - May 2013
If the past is a harbinger of the future, therapy for HCV infection will probably continue to advance at a brisk pace. Many additional potent agents are in the clinical pipeline, and interferon-free regimens are likely to dominate the HCV therapeutic landscape within the next 5 years.....
At this year's EASL in Amsterdam with over 9600 delegates the phase III study results for the two "second wave HCV protease inhibitors" faldaprevir and simeprevir each in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) for HCV genotype 1 patients were presented as well as the phase III findings for the polymerase inhibitor sofosbuvir again in combination with PEG-IFN/RBV for treatment of genotypes 1,4,5 and 6. In addition phase III results of the first interferon free combination of sofosbuvir with ribavirin for treatment of genotype 2 and 3 were presented....
Care for hepatitis C is evolving rapidly, with increasingly effective and better-tolerated antiviral therapies being evaluated and approved for use. It's clear, however, that not everyone who would qualify for therapy has been tested and identified, referred for appropriate care, and offered or given the best therapy available. Furthermore, currently used antiviral drugs - pegylated interferon and ribavirin "base" plus either telaprevir or boceprevir - can cost more than $70,000 for a full course of therapy. It is expected that the new oral antiviral agents will be just as expensive, at least in the short term.
Hepatitis C Therapy Update 2013-What About Interferon-free Regimens?
U.S. FDA grants priority review to Simeprevir (TMC435) for combination treatment of genotype 1 chronic hepatitis C
AbbVie's ABT-450- Breakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen
Gilead Sofosbuvir and ledipasvir: Plans to initiate a third Phase 3 clinical trial with and without ribavirin
Cost will limit uptake of off-label Gilead/Bristol-Myers Squibb Hep C combo, despite best-in-class data
ViewPoints: New Hep C data validates Gilead's solo approach
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir (GS-7977) for the Treatment of Hepatitis C-- Sofosbuvir Would Form Basis of First All-Oral Regimen for HCV Genotype 2 and 3 Patients, and Interferon-Sparing Regimen for Genotype 1 Patients --
Anemia Top Side Effect of HCV Antivirals
Hepatitis C Virus Infection: Looking for Interferon Free Regimens
Review: NS5A Inhibitors in the Treatment of Hepatitis
VX-135/daclatasvir: Vertex signs agreement with Bristol-Myers for all-oral midstage studies for hepatitis C treatments
Simeprevir (TMC435) - Janssen Submits New Drug Application to U.S. FDA
Miravirsen- Hepatitis C drug goes after patients’ RNA
Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients
Hepatitis C - Presidio Collaboration with Boehringer Ingelheim for interferon-free Phase IIa clinical trial
Gilead hepatitis C drug sofosbuvir (GS-7977) meets goal of fourth late-stage study
EASL-Burden of Liver Disease in Europe: Looks at leading causes of cirrhosis and primary liver cancer in Europe
Gilead Announces SVR Rates from Two Phase 3 Studies of Sofosbuvir (GS-7977) for Hepatitis C
Potential IFN-Free Regimens For HCV
IDX184 and IDX19368 - Idenix drops development of hepatitis C drugs
Interferon free regimens for the “difficult to treat”: are we there?
Current Prospects for Interferon-free Treatment of Hepatitis C in 2012
Numerous other DAAs are in clinical development, and phases 2 and 3 trials are evaluating interferon-free combination DAA therapy. Interferon-free sustained virologic responses have now been achieved with combinations of asunaprevir and daclatasvir; sofosbuvir and ribavirin; sofosbuvir and daclatasvir; faldaprevir and BI207127; ABT-450, ritonovir and ABT-333; ABT-450, ritonovir and ABT-072; miracitabine, danoprevir and ritonavir; and alisporivir and ribavirin. Some drugs are genotype-specific in their activity, whereas others are pan-genotypic, and differential responses for the genotype 1 subtypes 1a and 1b have emerged with many DAA combinations. Viral breakthrough and resistance are important considerations for future trial design. The prospect of interferon-free combination DAA therapy for hepatitis C virus is now finally becoming a reality.
2013-Guide to Clinical Trials for People with Hepatitis C
Bristol-Myers to Hold Talks On Settling Claims of Hepatitis C Patients
Treat Now or Wait?
The debate rather to treat HCV now or wait is ongoing, in the journal "Liver International" factors which affect the decision to treat now or delay therapy are discussed. You can view the article here: Patients with HCV and F1 and F2 fibrosis: treat now or wait?
Lucinda K. Porter, RN Shares A Personal Experience: Starting 12 weeks of sofosbuvir, GS-5885, and ribavirin
Coming in September 2013
A second book authored by Lucinda K. Porter, RN: Hepatitis C Treatment One Step at a Time: Inspirational Readings and Practical Tips for Successful Hepatitis C Treatment
FREE FROM HEPATITIS C
Clinical Trial Updates
ClinicalTrials.gov: updated in the last 30 days
HCV PipelineHCV Advocate - News & Pipeline Blog
Chronic Hepatitis C Infection: Treat Now or Wait?
INCIVEK® (telaprevir)-Updates label after reports of a ‘small number of fatal skin reactions’
Vertex discloses Hep C drug deaths
HCV Transplant Studies GS-7977 Also Telaprevir & Boceprevir
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
Hepatitis C–What Are Your Treatment Choices: New Webinar
Setbacks in HCV Drug Development Highlight Uncertainties in Treat or Wait Decisions
So You Think You’re a Hepatitis C Expert
Back in July Clinical Care Options released part one of a three part online quiz containing 35 questions on hepatitis C, answered by nine world-renowned hepatology experts. In October CCO released part two of the series which included case scenarios from 11 leading international experts on hepatitis C, and today part three was released!
Idenix: FDA Places IDX19368 Hepatitis C Treatment on Clinical Hold
IDX184-Idenix hepatitis C drug put on partial hold
BMS halts the development of BMS-986094 due to patient death
BMS-986094-Bristol-Myers Sued Over Heart Damage In Hepatitis C Drug Trial
The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), will take place April 24 to 28 in Amsterdam, The Netherlands.
EASL Website - Press Room
EASL Abstract Search
Click here for a downloadable PDF version of the Abstract Book.
Tips For Viewing Hepatitis C Abstracts
Download now the ILC 2013 congress app and have full access to the scientific programme, posters, abstracts, floorplans and more!
EASL: Direct-acting antivirals now ready for prime time with promising alternatives on the way
AbbVie is a new, independent biopharmaceutical company composed of Abbott’s former proprietary pharmaceutical business
ABT-267, ABT-333-non- nucleoside, ABT-450/r
r = ritonavir
Faldaprevir/ (BI 201335)
MK-5172 and Daclatasvir
MK-5172 and Daclatasvir-Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial
CCO's independent conference coverage
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Long-term management of the successful adult liver transplant: 2012 practice guideline by the -AASLD
VA guidelines for management and treatment of HCV, published in the American Journal of Gastroenterology
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
Nonalcoholic Fatty Liver Disease (NAFLD)
New Clinical Practice Guideline Developed for Nonalcoholic Fatty Liver Disease
2012-New guidelines on the management of hepatocellular carcinoma (HCC).
These guidelines result from a joint collaboration between the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC).
EASL-April 2012 Revised Clinical Practice Guidelines on the Management of Chronic Hepatitis B
HCV Information and Educational Resources
Clinical Liver Disease -Digital Liver Disease Journal
This journal is an official digital educational resource from the American Association for the Study of Liver Diseases.
Visitors are able to view videos, full data, and download files in either HTML or PDF formats
View all issues here.
Projects In Knowledge
Offered at the site is a program series of HCV Video Case Vignettes. In the videos individual patient case studies are discussed, topics include side effects, drug-drug interactions, treatment duration, and outcome.
AASLD - Liver Learning
If you haven't yet explored the "Liver Learning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more.
Other HCV Sites:
These links will take you to the premier Hepatitis C sites and keep you informed with breaking news, clinical studies, new drugs, podcasts, newsletters, support, personal experiences, chat rooms, forums and more.
2012 Articles Of Interest
2012-New Antiviral Agents for Hepatitis C
This article describes the direct acting antivirals and host-targeted agents that have recently been approved or have been tested in HCV-infected patients and discusses their two current paths of clinical development: with or without interferon-α.
Standardization of Terminology of Virological Response in the Treatment of Chronic Hepatitis C
Protease inhibitors: Silver bullets for chronic hepatitis C infection?
Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
A significant increase in the number of patients with CHC to be treated is expected for 2012, with triple therapy regimens that are more complex. These expected developments represent a significant challenge and will stretch current resources.
The present Swiss Association for the Study of the Liver (SASL) expert opinion statement is not intended as guideline but shall provide some guidance on the management of CHC genotype 1 and the use of TPV and BOC
If you have just been diagnosed with hepatitis C or considering HCV therapy click here for easy to understand information.
Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs
Prescribing Information for INCIVEK including the Medication Guide.
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.
- (PPI-668) w-Faldaprevir (BI201335) and BI207127 (1)
- 2012 -168 Pages Of HCV FAQs (1)
- A 2013 Conference on Retroviruses and Opportunistic Infections (4)
- A Guide 2011-Management Of HCV (2)
- A Guide 2012-Guideline for Nonalcoholic Fatty Liver Disease (1)
- A-2012 EASL-AASLD Special Conference (2)
- A-2012 Update on the Diagnosis and Treatment of Hepatitis C (1)
- A-2012-New guidelines on the management of hepatocellular carcinoma (HCC). (1)
- A-Current status and future directions in the management of chronic hepatitis C (1)
- a-DDW 2011 Meeting (11)
- a-DDW 2012 meeting (21)
- a-DDW 2013 meeting (17)
- A-EASL 2011 Summary (1)
- A-EASL 2012 (79)
- A-EASL 2012 - Guidelines on the Management of Chronic Hepatitis B (1)
- A-EASL 2012 Index (1)
- A-EASL 2012 Internet Symposium (2)
- A-EASL 2012 Summary Of The Meeting (1)
- a-EASL 2013 (50)
- A-EASL 2013 Summary Of The Meeting (1)
- a-EASL 2013-abstract search (1)
- A-New targets for antiviral therapy (82)
- A-Patients who will remain untreated in the era of triple therapy (1)
- AASLD 2011 updated hepatitis C practice guidelines (2)
- AASLD 2012-63rd Annual Meeting (73)
- AASLD 2012-STC (1)
- AASLD Nov 2011 (60)
- AASLD Nov 2011-Pocasts-Videos-Webcasts (2)
- AASLD Nov 2011-Summary (1)
- AASLD Oct2010 (80)
- AASLD Oct2010-summary (1)
- ABT-267 (10)
- ABT-333-non- nucleoside (11)
- ABT-450 (9)
- ABT-450/r (20)
- ABT-450/r and ABT-072 (4)
- ABT-450/r plus ABT-333 (8)
- Acai Berry Scam (1)
- acetaminophen (2)
- ACH-1625 (15)
- ACH-2684 (5)
- ACH-2928 (2)
- ACH-3102 (9)
- ACLF (1)
- acupuncture (2)
- acute HCV (4)
- acute HCV-when to begin therapy (1)
- acute liver failure (1)
- addiction (14)
- Adherence to therapy (12)
- ADI-PEG 20 (1)
- AIDS (2)
- alcohol consumption (12)
- alisporivir (4)
- alpha-fetoprotein (1)
- ALS-2200 (3)
- ALS-2200 (VX-135) (11)
- ALS-2200 and ALS-2158 (3)
- ALS2158 (1)
- amazing sunday (1)
- ANA598 (5)
- ANA598-setrobuvir (2)
- ANA773 (1)
- ANA958 (1)
- anemia (7)
- antidepressants (4)
- antioxidants (1)
- arthritis (4)
- ascites (9)
- asthma (1)
- Asunaprevir (1)
- autoimmune hepatitis (1)
- Avila Therapeutics™ (1)
- AVL-192 (2)
- bath salts-spice (12)
- Bavituximab (5)
- BCX5191 (2)
- BCX5191-withdrawn (1)
- Behind the Headlines (8)
- Behind the Headlines-Vaccine (1)
- Best Hospitals (5)
- BI 201335 and BI 207127 (10)
- BI 207127 (7)
- BILB 1941 (1)
- Bioartificial Liver (3)
- biological "devices" to program cells (1)
- Biopump (1)
- BioScience (2)
- biosimilars (6)
- BIT225 (2)
- BL-8020 (2)
- blood safety (2)
- blood scandal (3)
- bms-650032 (6)
- BMS-650032 (Asunaprevir) BMS-790052 (Daclatasvir) (10)
- BMS-650032 and BMS-790052 (5)
- bms-790052 (18)
- bms-790052-declatasvir (10)
- BMS-986094-INX 189 halted (8)
- BMS-986094-INX 189 on hold (7)
- boceprevir (98)
- Boceprevir FDA Transcript (1)
- boceprevir patient guide (1)
- boceprevir-drug assistance program (3)
- boceprevir-Medication Guide-Prescribing Info (1)
- boceprevir-victrelis (178)
- boceprevir-victrelis-Cost (1)
- boceprevir-victrelis-mericitabine w-SOC (1)
- Bowel (1)
- Brain (7)
- Caleco Pharma (1)
- Canada (2)
- cancer (14)
- cancerous growths gallbladder and/or the bile duct (1)
- CDC (4)
- CDC- World Hepatitis Day 2011 (1)
- CDC- World Hepatitis Day 2012 (4)
- Chat room (3)
- children treating HCV (15)
- chronic disease (2)
- chronic fatigue (16)
- chronic hepatitis c (2)
- chronic liver failure (2)
- chronic pain (3)
- cirrhosis (173)
- cirrhosis-complications (10)
- cirrhosis-Vibrio vulnificus-raw oysters (1)
- clinical trials (120)
- clinical trials-Pro-Con (4)
- coffee (21)
- Colloidal silver (1)
- colonoscopy (2)
- comorbidities HCV anti-viral treatment and disease (1)
- compensated cirrhosis (11)
- Complementary and Alternative Medicine (17)
- Counterfeit drugs (7)
- covalent inhibitor (2)
- Creating Functional Hepatic Tissue (1)
- Cryoglobulinemia (5)
- CTS-1027 (5)
- Cyclophilin Inhibitors (1)
- Daclatasvir (3)
- daclatasvir-peg/riba (3)
- Daclatasvir/Asunaprevir (3)
- daclatasvir/asunaprevir/BMS-791325 (5)
- Daily Consensus Interferon (1)
- Danoprevir (12)
- Danoprevir/Mericitabine (2)
- DEB025 (2)
- DEB025- alisporivir (4)
- decompensated cirrhosis (18)
- Dental (3)
- Depression (16)
- diabetes (100)
- diabetes-insulin resistance (8)
- Digestion (2)
- Direct-acting Antivirals (11)
- disease progression (11)
- donation (13)
- drug alerts (1)
- Drug Assistance Programs (5)
- Drug Resistance Test (1)
- drug shortages (1)
- dry eye (3)
- dyspepsia (1)
- EASL (59)
- Economic Burden HCV (2)
- ELAD® Bioartificial Liver (1)
- encephalopathy (28)
- endoscopy (1)
- Epidemic HCV (9)
- Epogen (4)
- ESLD (1)
- faldaprevir (7)
- faldaprevir/ (BI 201335) (24)
- faldaprevir/BI 207127 (1)
- fatigue (7)
- Fatigue-Cognitive Function-Sleep Quality (2)
- Fatty Liver (113)
- Fatty Liver-RP103 (1)
- FDA (68)
- fibromyalgia (7)
- Fluvastatin (2)
- Foodborne illness (15)
- G7128 (1)
- gallbladder (1)
- gallstones (9)
- gastritis (1)
- Gastroenterologist (1)
- geno 2 (16)
- geno1 (92)
- geno2 (32)
- geno3 (53)
- geno4 (28)
- geno5 (5)
- geno6 (10)
- genotypes;All (14)
- green tea (2)
- GS-5885 (4)
- GS-7977 now Sofosbuvir (65)
- GS-7977 now Sofosbuvir and simeprevir (TMC435) (6)
- GS-7977 now sofosbuvir / GS-5885 now ledipasvir (14)
- GS-7977 now Sofosbuvir Plus Riba (2)
- GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir (10)
- GS-7977 Plus Peg/Riba (3)
- GS-9190 (7)
- GS-9256 (6)
- GS-9451 (2)
- GSK2336805 (3)
- Gut Bacteria (1)
- H pylori (1)
- HALL OF SHAME (42)
- HALT-C (8)
- hav (6)
- hav vaccine (1)
- hbv (96)
- hbv vaccine (1)
- HCV Australia (6)
- hcv abstracts (231)
- HCV Awareness (69)
- HCV Awareness-screening strategies (19)
- HCV Baby Boomers (31)
- HCV cardiovascular disease (1)
- HCV diet (3)
- HCV Forum (1)
- HCV hypertension (1)
- HCV natural compounds (1)
- HCV neurocognitive function (1)
- HCV News (1277)
- HCV News-weekly rewind (20)
- HCV pregnancy (6)
- HCV Protease Inhibitors in Active Drug Users (1)
- HCV replication (3)
- HCV research (93)
- HCV Self-management (1)
- HCV symptoms (3)
- HCV tests (19)
- HCV tests-endoscope (1)
- HCV transmission FAQ (1)
- HCV Vaccine (24)
- HCV vaccine GI-5005 (7)
- HCV Vaccine-TG4040 (MVA-HCV) (2)
- HCV Worldwide (29)
- HCV Worldwide Asia Australia Egypt (2)
- HCV Worldwide-Europe Canada Israel (1)
- HCV Your Health (3)
- HCV-autoimmune diseases (1)
- HCV-Breast Cancer Risk (1)
- HCV-Editorial (12)
- HCV-Education (56)
- HCV-elderly (3)
- HCV-Insulin resistance (11)
- HCV-Statins (7)
- HCV/HBV/HIV special populations (1)
- Health Reform (3)
- Health Reform-Insurance (4)
- Healthy you (28)
- hemochromatosis (1)
- HepaFat™ (1)
- Hepatitis-related Renal Disease (1)
- hepatocyte cell transplantation (1)
- hepatologist (1)
- hepatoSys Virtual Liver Network (1)
- herb (31)
- herb-kava (2)
- HEV (3)
- History of HCV (3)
- HIV (114)
- HIV-children (3)
- hiv/hbv-coinfection (1)
- HIV/HCV (70)
- hot topic (9)
- HTAs-host-targeting agents (1)
- human genome (6)
- human interferon alpha lozenges (2)
- Idenix Reports Positive Interim Data for Hepatitis C Drug (1)
- IDX184 (21)
- IDX184-Discontinued (1)
- IDX19368-Discontinued (1)
- IDX19368-hold (2)
- IDX719 (9)
- if I had.. (9)
- IFNL 4 (1)
- IL-7(CYT 107) (1)
- IL28B (62)
- IL28B Test (2)
- immune system (9)
- IMO-2125 (6)
- Inflammation (3)
- Inflammation Liver (1)
- Inflammatory Bowel Disease (1)
- INFRADURE Biopump (1)
- Inspirational (25)
- Insurance (1)
- Insurance medicare (1)
- interferon (5)
- Interferon Free Combinations (111)
- Interferon lambdas (1)
- interferon-free therapies (3)
- Investment News HCV Drugs (22)
- INX 189 (13)
- IP-10 (1)
- ITX-5061 (1)
- Joint pain (1)
- Just for fun (5)
- JX594/TG6006 (2)
- Lambda (7)
- ledipasvir (GS-5885) (4)
- Lichen Planus (5)
- List Peer-Reviewed Journals (2)
- Liver Abscess (2)
- liver biopsy (13)
- liver biopsy-necessary in all genotypes? (1)
- liver cancer (228)
- Liver cancer CF102 (2)
- Liver Cancer Treatment (73)
- liver cancer treatment-radiofrequency ablation (RFA) (2)
- Liver Cancer-HEAT Study of ThermoDox(R) (3)
- liver cancer-MCT-465 and MCT-485 (1)
- liver cancer/sorafenib (4)
- Liver Cysts (1)
- liver disease (15)
- Liver Fibrosis (96)
- liver function tests (12)
- liver health (66)
- Liver Injury Dietary Supplements (2)
- Liver Injury-Shark liver oil (1)
- Liver Pain (6)
- liver surgery (2)
- liver/anatomy (1)
- locteron (1)
- Locteron/interferon (2)
- lymphoma (3)
- M11-602 (1)
- marijuana (27)
- marijuana-based prescription drug (1)
- MBX-700 and MBX-701 (formerly SCH 900942 and SCH 900188) (1)
- Mediterranean diet (1)
- Men and HCV (4)
- microspheres (3)
- Milk thistle (22)
- Miracle Mineral Solution-MMS (1)
- Miravirsen (7)
- miRNAs (1)
- MK-5172 (11)
- MK-5172/peg/riba (1)
- MK-5172/Vaniprevir(MK-7009) (1)
- MK-7009 (4)
- monoclonal antibody GS-6624 (1)
- Morbidity-SVR (3)
- Mortality (12)
- myocardial infarction (1)
- myocarditis (1)
- nanoparticles (3)
- Nanotechnology (3)
- Natural leukocyte interferon alpha (Alfaferone) (1)
- Neutropenia HCV Treatment (4)
- new drugs (3)
- new hcv drugs (55)
- newly diagnosed (8)
- newsletters (45)
- Nitazoxanide (2)
- noninvasive tests for fibrosis (36)
- nonresponders (7)
- NS5A inhibitor (2)
- NSAID (7)
- nucleoside inhibitors (1)
- null responders (10)
- occult hepatitis C virus infection (1)
- Off Topic (31)
- online pharmacy (1)
- Oral interferon (1)
- organ harvesting (11)
- organ trafficking (5)
- organ trafficking- U.S (1)
- organ-imported tainted tissue (1)
- Origin Of Hepatitis (1)
- Other Conditions Related To HCV (46)
- Other Conditions Related To HCV-Vasculitis (5)
- Other Health News (91)
- OTHER INFECTIOUS DISEASE (20)
- outsourcing clinical trials (3)
- outsourcing drugs (7)
- partial responders (3)
- Pediatric liver disease (1)
- Pegasys (10)
- Peginterferon (74)
- PegIntron (4)
- Peripheral Neuropathy (2)
- PF-05095808 (1)
- Pharmaceuticals (135)
- Pink eye-Sty-and other eye conditions (1)
- platelets (3)
- polymerase inhibitor (16)
- Porphyria Cutanea Tarda (PCT) (2)
- Post Treatment Symptoms (1)
- PPI-383 (1)
- PPI-461 (3)
- PPI-668 (3)
- primary biliary cirrhosis (PBS) (1)
- probiotics (1)
- procrit (4)
- prognostic test:response to therapy (1)
- promacta (1)
- prostate cancer (1)
- protease inhibitor (33)
- protease inhibitor- (NS3/4A) Drug Resistance Test (2)
- PSI-7977 (24)
- PSI-7977 and PSI-938 (1)
- PSI-7977-TMC435 (3)
- PSI-7977/ Daclatasvir-(BMS-790052) (1)
- PSI-938 (6)
- PSI-938-Halted (1)
- Pulmonary fibrosis (1)
- Quackery (10)
- Questions About HCV (4)
- rash (10)
- recall (25)
- regeneration (5)
- regenerative Medicine (15)
- relapse (8)
- resistance to protease inhibitors (16)
- response-guided therapy (4)
- RG7128 (9)
- ribavirin (25)
- Ritonavir (1)
- rituximab (2)
- salt (4)
- SB 9200 (1)
- scientists grow human livers in laboratory (7)
- SCY-635 (5)
- SCY-641 (1)
- Seasonal Flu Vaccine (9)
- selenium (2)
- setrobuvir (1)
- side effects (65)
- side effects-direct-acting antivirals (18)
- side effects-eyes (7)
- side effects-telaprevir (3)
- silibinin (4)
- silymarin (4)
- Simeprevir (11)
- SIR-Spheres microspheres (2)
- Small fiber neuropathy (2)
- Sorafenib (6)
- sovaprevir (3)
- Sovaprevir (Formerly ACH-1625) (5)
- Sovaprevir/ACH-3102 (2)
- sphincter of Oddi (3)
- spleen (6)
- SPONTANEOUS CLEARANCE (12)
- Standardization of Terminology of Virological Response (1)
- Starting HCV Treatment (69)
- STAT-C (3)
- stem cell lawsuit (2)
- stem cell tourism (7)
- stem cell-diabetes (1)
- stem cells (76)
- stem cells-pluripotent (2)
- stem-cell-derived liver tissue model (1)
- supplements (13)
- support (45)
- support-hotline (5)
- Surgery in liver disease (2)
- svr (68)
- SVR-Mortality (4)
- svr-pitavastatin (Livalo) (1)
- svr-rapid response (1)
- SVR24-SVR12-SVR4 (8)
- Tattoos (2)
- telaprevir (125)
- Telaprevir FDA Transcript (1)
- telaprevir medication guide (1)
- telaprevir patient assistance (3)
- telaprevir prescribing information (1)
- telaprevir with VX-222 (20)
- telaprevir-incivek (205)
- telaprevir-incivek-Cost (3)
- Tenofovir (2)
- Terry's nails (1)
- TG4040 (2)
- Thalidomide (1)
- The natural history of hepatitis C (2)
- Therapy-over the age of 65 (1)
- TheraSphere (1)
- Thrombocytopenia (4)
- Thrombocytopenia-Promacta (1)
- thrombosis (3)
- thyroid (11)
- Timeline Hepatiits (1)
- TMC278 for HIV (1)
- TMC435 (26)
- TMC435 (Simeprevir) (27)
- TMC435-BMS-790052 (3)
- TMC647055 (3)
- TMC647055 and IDX719 (1)
- TMC649128 (4)
- toxicity (25)
- transmission (64)
- Transmission clinical setting (84)
- Transmission clinical setting-Government Report 2012 (1)
- Transmission of HCV Through Transplanted Organs (2)
- transmission-needlestick (2)
- transplant (162)
- transplant tourism (7)
- Transplant- Telaprevir/Boceprevir (3)
- transplant-certican (1)
- Transplant-GS-7977 now Sofosbuvir (1)
- transplant-HCV recurrence (2)
- transplant-IL28B (1)
- transplant-MELD (6)
- Triad Prep Pads (16)
- TT-034 (1)
- tylenol (11)
- upper abdominal pain (2)
- varices (14)
- video (259)
- video viral load test(PCR) (1)
- viral load (9)
- Virtual Liver (1)
- virus research (2)
- vitamin A (6)
- vitamin B12 (3)
- vitamin D (34)
- vitamin E (6)
- Vitamin E-TE/TCP supplements (1)
- vitamin k (1)
- vitamins (7)
- warning-black cohosh (1)
- weekend reading (42)
- wellness (52)
- what is hepatitis c (1)
- women (8)
- Xifaxan (1)
- XIX International AIDS Conference (4)
- zalbin (1)
- zinc (1)
- ► 2013 (438)
- ► 2012 (1293)
- ► 2011 (1577)
- Stanford: Researchers engineer biological "devices...
- Today, on the 22nd World AIDS Day
- Interim Results TMC435 Works in Treatment-experien...
- Hepatitis C December Newsletter: IL28B Gene Highli...
- Tricyclic antidepressants (TCAs) associated with 3...
- Liver Cancer: Video Understanding SIR-Spheres micr...
- SIR-Spheres microspheres Option For Inoperable Liv...
- Hepatitis C Contracted During Holiday/Dialysis Rec...
- Hepatitis C: Caleco files amendment that resulted ...
- Hepatitis C: PSI-7977 and PSI-938 Pharmasset Initi...
- Hepatitis C/Liver How Stem Cells Work
- If HCV Treatment Relapse Occurs, It Occurs Quickly...
- Hepatitis B PCR-based molecular diagnostic solutio...
- FG-2216 New Drug To Treat Anemia in dialysis patie...
- Hepatitis C News: FDA Approves Merit Phase 3 clini...
- Hepatitis C: Interferon-associated retinopathy
- Merck halts study: HIV integrase inhibitor raltegr...
- Laparascopic finding predicts hepatocellular carci...
- Premature ageing can be reversed by reactivating a...
- Hepatitis scandal
- Immunitor issued a key patent for Oral Vaccine Te...
- Small fiber neuropathy: A burning problem
- Small-Fiber Neuropathy and Hepatitis c
- Liver Transplant Updates Nov 28th
- Hepatitis infections in Pakistan/ 7% suffering fro...
- Hepatitis C: Avilomics™ platform to design covalen...
- Sunday Spotlight Hepatitis C Drug Danoprevir : (RG...
- Hepatitis C : Dry Mouth/Causes and Solutions
- Marijuana In The News
- Hepatitis C Morning News:RG7128 Nov 27th
- What Goes Wrong in the Liver with Cirrhosis?
- Blood tests predict mortality following liver rese...
- HIV Video: Possible Method to Preventing HIV, Stat...
- Human genome: The first synthetic species
- Hepatitis C : (SIRT) is a targeted treatment for l...
- Hepatitis C In The News Nov 26th
- Facts About Decompensated Liver Disease
- Hepatitis C News: Nurse Charged In Hep C Scandal
- Dr. Anthony Fauci on Potential Breakthrough in AID...
- Reluctance to start statins in patients with out-o...
- Steroid use in the Army has been on the rise amid ...
- Hepatitis C News : Nov 24th
- FAQ : What You Need To Know About Telaprevir
- Cardiac operations in patients with cirrhosis
- Gilead Sciences Submits New Drug Application to U....
- Roche terminates agreement: Prohibited to develop ...
- Its Happening ! Telaprevir Files FDA Seeks FAST T...
- Telaprevir FDA Submission Complete Seeking Approva...
- All About Liver Cancer
- Hepatitis C genotypes in severity of liver disease...
- Off Topic:Fake Tissue For Med Students
- Biological Attack? Hepatitis C Hemopurifier may be...
- Hepatitis C On Wall Street: The Scandals Nov 22 20...
- Uptake of hep C treatment in opiate substitution t...
- Management of chronic Hep B in HIV positive patien...
- Hepatitis C News:Hepachronix project, focus on new...
- Stopping rule based on baseline anti-NS4a antibody...
- Inside Story Of The Living Cell
- Hepatitis C News Nov 21: Murder in Your Hospital ...
- Hepatitis C Support : Spotlight Sunday
- Hepatitis C Wellness: Fatty Liver Disease
- Decompensated cirrhosis
- Hepatitis C : Liver Pain
- Hepatitis C Wellness: Artichokes
- Laparoscopic liver resection for malignant tumors ...
- Hepatitis C: In The News Nov 20th
- Advances made in developing hepatitis C vaccine
- FDA recommends against the continued use of propox...
- RECALL List: Smoked turkey sold by New Braunfels S...
- Podcast:Converting skin cells straight into early ...
- Regenerative Medicine: Growing more than 20 types ...
- Hepatitis C News: What is IL28B Gene?
- Off Topic: Animal genomes "The Roots Of A Virus"
- Skin findings In Hepatitis C
- Hepatitis C :challenges in the management of STAT-...
- Video:LJWG conference on Hepatitis C
- Hepatitis C Drug Development Progress/Telaprevir, ...
- Hepatitis C Is Not Just A Celebrity Disease:Mornin...
- TMC435 positive interim data on Phase 2b ASPIRE st...
- Treatment of Hepatitis C in 2011
- Nausea and vomiting,abdominal pain associated with...
- 65 Years/Or Older:Predictors to treatment response...
- Hepatitis C Bail set $3 million For Dr. Benhamou I...
- Combination therapy improves survival time for pat...
- Hepatitis C Morning News Nov 17th
- Off Topic: Mickey Mouse Doctors
- Human Genome Sciences
- The SOC For Hepatitis C Will Change Significantly ...
- Hepatitis C News Nov 16th: The Good, Bad and ?
- Hepatitis C–related arthropathy
- Liver Treatments:Body Radiation Therapy (SBRT)
- Danger of Combining Warfarin with Herbal and Dieta...
- Protease Inhibitor-Resistant Hepatitis C Virus
- More fat around internal organs may mean more comp...
- Live-donor liver transplantation
- Hepatitis C:Telaprevir is Effective Given Every 8 ...
- Hepatitis C In The News Nov 15 2010
- Audio:Hepatitis C Unresectable liver cancer by tem...
- Pain Linked With Poorer Prognosis in Liver Cancer
- Predictors of early treatment discontinuation in H...
- Growing human embryonic stem cells in the lab is n...
- Hepatitis C Video: Natalie Cole
- The Future of Hepatitis C/ Informational Video
- Liver News: StemCells, Inc. Launches New Website
- Hepatitis C: FDA Sunday
- Video/A National Strategy for Viral Hepatitis Cont...
- hepatitis C virus genotypes and subtypes among Lib...
- Hepatitis C Treatment: current and future perspect...
- HCV And HCC Updates: ThermoDox® To Treat Primary L...
- Hepatitis C News
- *Liver Growing Body Parts *Regenerative medicine
- Life Cycle Of The Hepatitis C Virus
- Hepatitis:Common Blood Tests/Liver Function
- Hepatitis C New Drugs:Telaprevir,Boceprevir Potent...
- Video:AASLD Changing The Way We Treat Hepatitis C
- Hepatitis B Video/Nov 12 2010
- Liver Regeneration:Opening The Door To New Treatme...
- Chemo Combo for Biliary Tract Cancer Successful
- Underactive thyroid and associated risk for heart ...
- Dr. Temporarily Removes Liver To Treat Liver Cance...
- Study Suggests Way to Treat Liver Cancer
- Drinking can weaken the immune system
- non-invasive tool for assessing liver fibrosis in ...
- (NAFLD)Carbohydrate Restriction Fastest Way to Red...
- Predictors of early treatment discontinuation amon...
- Coalition Launches Campaign Supporting Embryonic S...
- Hepatitis C in Pregnancy
- Hepatitis C Therapy:W-Peg/Riba decreases in body w...
- Hepatitis C Oral Therapy SCY-635 Receives Federal ...
- Hepatitis C Newsletter: November
- HCV NEEDS A FAT ENZYME
- Hepatitis And Your Health In The News
- 2010 Hepatitis C:After 30yrs 15%–35% will develop ...
- Phase I ALN-VSP Trial Data /Liver Cancer
- Cirrhosis: What Happens When The Spleen Is Enlarge...
- 'OK In Your Zone' Tour:Hepatitis B Is Mean, Don't ...
- Children with hepatitis C fare decidedly better wi...
- 83.8% Of Doctors Have Some Sort Of Connection W-Dr...
- Hepatitis C:Telaprevir/VX-222 Phase 2 Enrolling Ad...
- Questions and Answers About Milk Thistle/2010
- Safe injections Protecting Millions From Hepatitis...
- Video: Liver Cancer Interview with John D. Groopma...
- AASLD 2010 Summary Of Hepatitis C Oral Inhibitors
- 2010 AASLD Conference News At Medscape
- Abnormal Liver Histology in HIV-Positive Patients
- Telbivudine Prevents Hepatitis B Perinatal Transmi...
- Hepatitis C Short-Course Telaprevir Equal to Full-...
- Food Safety Report :Keeping Food Safe from Farm to...
- Leaders in academic medicine ask Congress to pass ...
- Thirteen Myths About Rheumatic Diseases
- Fibromyalgia can be experienced concurrently with ...
- Hepatitis C:Genes in Ribavirin-Induced Anemia
- Proof of concept for the therapeutic vaccine GI-50...
- Skin cells transformed into blood
- Bone loss common in patients with HIV,
- Why does cancer relapse?
- Hepatitis C Drugs: R7128 with the protease inhibit...
- Hepatitis C Follow-Up of HALT-C Some Benefit of In...
- Audio:AASLD Viral Hepatitis:Confronting a Silent E...
- AASLD:5 New Potent HCV Protease inhibitors Coverag...
- Hepatitis C In The News Nov 2010
- AASLD Best Of The Liver Meeting:Treatment Hepatiti...
- Hey,I Have Questions About Cirrhosis And My Liver....
- Counterfeit/substandard medicine:Snake Oil Vendors...
- Hepatitis C/Aplastic Anemia Asso/w Interferon Alph...
- Getting A Safe Tattoo
- "Low Vitamin D Ups Mortality Risk in Patients With...
- Final results phase-3 studies of boceprevir
- Off Topic: A Break From The News This Sunday Folks...
- AASLD: Hepatitis C protease inhibitor ABT-450
- Hepatitis C in type 2 diabetes: Evidence for a pos...
- AASLD: New Hepatitis C Drugs At NATAP
- Video:Type 2 diabetes bouts with severe hypoglycem...
- New Funding of International Stem Cell Corporation...
- Cirrhosis With Large Varices Adding Probiotics to ...
- Hepatitis C: Why Do Nonresponders Not Respond
- Noninvasive Test For Measurement of Hepatic Steato...
- Salk scientists discovered how stem cells respond ...
- 2.5 cups of coffee daily reduced risk of hepatic s...
- Hepatitis C Trial:The Doctor and The Hedge Fund Ma...
- Thyroid and Hepatitis C
- Hepatitis C:Clinical Trial Information
- Multiple hepatitis C virus infections among inject...
- Hepatitis C Treatment-Related Anemia Assoc w-Highe...
- Researchers Call for Reassessment:Cirrhosis Classi...
- Respiratory insufficiency/pulmonary complications ...
- Increased Risk of Hip/Wrist Fractures in Cirrhosis...
- (ANA) Video/Nurse Contracted Hepatitis C/HIV Renew...
- The conversation just about over about donor gende...
- AASLD:Hepatitis C/HBV Audio/PIs Boceprevir/Telapre...
- Mandatory Curbs On Salt Reduces Stroke Rate
- Avila Presents Data On Their Hepatitis C Drug AVL-...
- The importance of organ donation
- Way Back Wednesday/Medical Quackery
- AASLD:BMS-790052 plus BMS-650032/comb Peg/RBV See ...
- VIDEO:New Drugs for Hepatitis C Patients/protease ...
- AASLD:Making News Hepatitis C Drug:TMC435
- AASLD:SVR for hepatitis C boon to patients 20 yrs ...
- 10 medical innovations 2011:Hepatitis C protease i...
- Liver Cancer:Trial of curaxin CBLC102 (quinacrine)...
- Cirrhosis:Diet and cognition in chronic liver dise...
- Urine color in cirrhosis or acute viral hepatitis
- Liver Cancer Survival Similar in HIV-Positive/HIV-...
- AASLD: TMC435 Rapid Response for Once-Daily Protea...
- What Is Hepatic Encephalopathy
- AASLD:GI-5005 Therapeutic vaccine plus peg-IFN/rib...
- New method to create bioartificial organs
- Liver hormone is a cause of insulin resistance
- Why Aren’t There AIDS-Style Cocktails for Hepatiti...
- ANA958:Hepatitis C Drug Speeds Viral Clearance
- New Hepatitis C Drugs GS-9256,GS-9190 Need riba/pe...
- AASLD:Hepatitis C Drug Boceprevir Six Months of No...
- Hepatitis C: Drug Companies and Doctors get greedy...
- Hepatitis C Drug INX-189 Polymerase Inhibitor Pres...
- New tool developed to predict success of hepatitis...
- AASLD:Video/Vitamin E Resolves NASH*non alcoholic ...
- AASLD:HCV Protease Inhibitor Danoprevir is Positiv...
- Evaluation of Acute Hepatitis C Infection Surveill...
- HCV genotype 1 was associated with a higher cumula...
- 2010/Telaprevir/Boceprevir SVR all Trials *geno 1,...
- AASLD: Video Antibiotic Reverses Cognition Loss in...
- AASLD:Men may be higher-quality liver donors than ...
- AASLD:Video/HCV/'Cure' Now on Agenda-Soon A Winnab...
- AASLD:Telaprevir SVR/Decreased Adverse Events Pres...
- AASLD Presented Nov 2/Final Results of Clinical Tr...
- AASLD:Control of Viral Hepatitis and Liver Cancer
- AASLD: The Wall Street Journal Reports
- Mortality rates from liver diseases underestimated...
- Roche Two Fines/One For Pegasys:Monies Paid To Nu...
- Hepatitis C Polymerase Inhibitor INX-189 Phase 1b...
- AASLD:Locteron/interferon,less adverse flu-like ef...
- Drug Therapy Okay for Pregnant Women With HBV
- Diabetes Meds Diminish Markers of Fatty Liver/AASL...
- AASLD: HBV New Target for HIV Drug
- HCV Tx Cuts Deaths Post-Transplant/AASLD
- AASLD:Human Cells Grow on Animal Liver Scaffolds
- ▼ November 2010 (236)
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ?
After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
- New HCV Drugs
- Keeping current on the potential arrival of new improved hepatitis C drugs. As once a hepatitis C patient myself (I successfully treated the virus with standard HCV therapy in 2000) I understand the difficult decisions and overwhelming fear that ensues after being diagnosed with this serious and life-changing disease. This blog serves as a starting point for information on the rapidly evolving number of new agents in development to treat hepatitis C. Tina